Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$3.91
-0.3%		$3.77
$2.60
▼
$14.68
$34.02M1.21144,053 shs23,266 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$3.51
-4.1%		$4.55
$0.72
▼
$20.32
$33.84M1.238,998 shs36,199 shs
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.16
$13.48
$15.15
▼
$28.77
$10.13M1.6229,886 shsN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.00
+0.7%		$1.16
$0.96
▼
$3.95
$37.78M0.69142,733 shs146,836 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
0.00%-3.22%+8.61%-0.76%-69.26%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
0.00%-9.07%-24.68%-49.93%+29.04%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00%0.00%0.00%0.00%+1.29%
Metagenomi, Inc. stock logo
MGX
Metagenomi
0.00%-1.96%-13.79%-21.26%-68.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$3.91
-0.3%		$3.77
$2.60
▼
$14.68
$34.02M1.21144,053 shs23,266 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$3.51
-4.1%		$4.55
$0.72
▼
$20.32
$33.84M1.238,998 shs36,199 shs
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.16
$13.48
$15.15
▼
$28.77
$10.13M1.6229,886 shsN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.00
+0.7%		$1.16
$0.96
▼
$3.95
$37.78M0.69142,733 shs146,836 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
0.00%-3.22%+8.61%-0.76%-69.26%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
0.00%-9.07%-24.68%-49.93%+29.04%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00%0.00%0.00%0.00%+1.29%
Metagenomi, Inc. stock logo
MGX
Metagenomi
0.00%-1.96%-13.79%-21.26%-68.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Briacell Therap stock logo
BCTX
Briacell Therap
1.00
SellN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
2.67
Moderate Buy$5.0042.45% Upside
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00
N/AN/AN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
2.75
Moderate Buy$6.00500.00% Upside

Current Analyst Ratings Breakdown

Latest GLYC, MGX, EDSA, and BCTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/21/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/9/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/26/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/12/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$7.00
7/23/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Briacell Therap stock logo
BCTX
Briacell Therap
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A$9.20 per shareN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.45 per shareN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$10K1,013.15N/AN/A$0.08 per share1.96
Metagenomi, Inc. stock logo
MGX
Metagenomi
$25.21M1.50N/AN/A$4.22 per share0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Briacell Therap stock logo
BCTX
Briacell Therap
-$26.31M-$7.92N/AN/AN/AN/A-153.53%-129.26%N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$7.19M-$1.69N/AN/AN/AN/A-560.22%-105.74%12/11/2026 (Estimated)
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%N/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$87.87M-$2.49N/AN/AN/A-384.61%-63.65%-44.52%11/10/2026 (Estimated)

Latest GLYC, MGX, EDSA, and BCTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q3 2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.4350-$0.60-$0.1650-$0.60N/AN/A
8/10/2026Q2 2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.5531-$0.73-$0.1769-$0.73$3.01 million($0.26) million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/AN/AN/AN/AN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
7.07
7.07
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
2.76
2.76
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/A
1.92
1.92
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
4.50
4.50

Institutional Ownership

CompanyInstitutional Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
75.19%
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A

Insider Ownership

CompanyInsider Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
0.74%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
24.40%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
8.70%
Metagenomi, Inc. stock logo
MGX
Metagenomi
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
48.70 million8.64 millionNo Data
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
179.64 million7.29 millionNot Optionable
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
5064.53 million58.90 millionNo Data
Metagenomi, Inc. stock logo
MGX
Metagenomi
11337.78 million33.06 millionN/A

Recent News About These Companies

Metagenomi (NASDAQ:MGX) Stock Price Down 7.7% - What's Next?
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081488
Contrasting Metagenomi (NASDAQ:MGX) and BioMarin Pharmaceutical (NASDAQ:BMRN)
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078031
Metagenomi updates hemophilia A gene editing program
September 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/metagenomi-updates-hemophilia-a-gene-editing-program?utm_source=marketbeat.com&utm_medium=referral
Metagenomi (NASDAQ:MGX) Director Laurence Reid Purchases 20,000 Shares of Stock
September 12, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mgx-insider-buying-and-selling-2026-09-12/
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354046/0/en/metagenomi-therapeutics-inc-to-present-at-the-wells-fargo-21st-annual-healthcare-conference.html
Metagenomi Therapeutics Inc MGX
August 25, 2026  |  morningstar.comM
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
August 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-metagenomi-therapeutics-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302859292.html
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
August 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938987-mgx-resources-limited-mtgry-q4-2026-earnings-call-prepared-remarks-transcript
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)
August 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3794251/analysts-top-healthcare-picks-metagenomi-inc-mgx-kymera-therapeutics-kymr/
Metagenomi Therapeutics: Q2 Earnings Snapshot
August 10, 2026  |  chron.comhttps://www.chron.com/business/article/metagenomi-therapeutics-q2-earnings-snapshot-22382477.php
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/metagenomi-therapeutics-reports-business-updates-and-second-quarter-2026-financial-results-1036437877
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972338/metagenomi-therapeutics-mgx-reports-q2-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2972338
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript
July 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4923569-mgx-resources-limited-mtgry-q4-2026-earnings-call-transcript
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327674/30541/en/prolynx-names-simon-harnest-as-chief-financial-officer-and-amer-mirza-phd-as-chief-scientific-officer-as-it-advances-multi-program-obesity-and-metabolic-disease-portfolio.html
Metagenomi Announces Board Changes and Shareholder Meeting Results
June 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/metagenomi-announces-board-changes-and-shareholder-meeting-results?utm_source=marketbeat.com&utm_medium=referral
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
June 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-metagenomi-therapeutics-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302792930.html
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302769/0/en/metagenomi-therapeutics-inc-to-present-at-the-jefferies-global-healthcare-conference.html
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/metagenomi-therapeutics-mgx-price-target-decreased-by-1071-to-850/ar-AA23aNXU
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/metagenomi-therapeutics-inc-nasdaq-mgx-134209184.html
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
May 12, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/metagenomi-therapeutics-reports-business-updates-and-first-quarter-2026-financial-results-1036139191

New MarketBeat Followers Over Time

Media Sentiment Over Time

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$3.91 -0.01 (-0.26%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$3.91 0.00 (-0.10%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$3.51 -0.15 (-4.10%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$3.64 +0.13 (+3.59%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

GlycoMimetics stock logo

GlycoMimetics NASDAQ:GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Metagenomi stock logo

Metagenomi NASDAQ:MGX

$1.00 +0.01 (+0.68%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.00 +0.00 (+0.10%)
As of 10/9/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas